费斯治疗

最新新闻

• BTIG Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Citi Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  TD Cowen Initiates Faeth Therapeutics(FTH.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  H.C. Wainwright Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• Needham Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  Oppenheimer Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Oppenheimer Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• H.C. Wainwright Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Citizens JMP Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $51
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• 评级变动
  Raymond James Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Guggenheim Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  Baird Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• Lucid Capital Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $59
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  JonesTrading Initiates Faeth Therapeutics(FTH.US) With Buy Rating, Announces Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/4

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。